Track the 바이오노트 share price and the full directors' dealings record of the company, a listed equity based in South Korea. Shares are listed on KR KR, under the authority of DART (FSS). Operating in the Health Care sector, 바이오노트 has logged 31 reports. Market capitalisation: €452.4bn. The latest transaction was reported on 29 May 2026 (Purchase). Among the most active insiders: 조영식. All data is accessible without an account.
31
Insider Decl.
n/a
Thresholds
€1m
13 ops.
Buy Volume
n/a
1 ops.
Sell Volume
32Σ signal
Buys €1mn/a Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 22,212 of 27,969 companies
31.0
score / 100
Value
29
Quality
33
FCF yld1.4%
Earn yld-19%
EV/EBITDA·
ROE-3.2%
Gross mgn56%
Net mgn-74%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
BioNote is a company specializing in the health and pharmaceutical sector, listed on the XKRX market. It focuses on the development of biological and diagnostic products.